The chipmaker spawned the term “patent troll” and has been highly critical of NPEs, but negative business headwinds mean that putting its world-class portfolio of IP assets to work is a no brainer
The guide provides industry executives with a deeper understanding of the strategic and legal IP challenges that they face, and how to overcome them
Such actions won’t derail litigation disputes but can prove an important bargaining chip when negotiating SEP licensing deals
Food brand values have returned to pre-pandemic levels, according to a new report
18 August 2022
The Portuguese president of the agency was recently appointed to a second term and now has until the end of June 2028 to leave an indelible mark on Europe’s patent story
18 August 2022
Although it is tempting to think that such rights are too difficult to secure, there are ways through to getting meaningful protection from the EPO
18 August 2022
The US District Court for the District of Delaware has seen a patent case surge as Judge Alan Albright’s docket shrinks
17 August 2022
New market entrant Terran Biosciences takes action against rival Compass Pathways in Maryland district court
17 August 2022
The company may have a small IP team but it has consistently proved its worth over a number of years
17 August 2022
In an exclusive interview, the company’s CEO Jacob Babcock details its journey to becoming a technology licensing business
16 August 2022
After a lull in biologic versus imitator disputes, Regeneron has sued Mylan and more litigation is likely to follow
16 August 2022
In an exclusive interview Biocon Biologics’ chief IP counsel explains the issues that he and his team focus on – and how an upcoming, big-ticket merger will lead to change
16 August 2022
Despite holding thousands of patents and being active for over 20 years, Docket Navigator data shows that the firm’s entities have filed just 32 litigation actions since 2008
15 August 2022
Get unlimited access to all IAM content
